



1635

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


Application Number	09/659,860
Filing Date	September 11, 2000
First Named Inventor	Hong Zhang
Group Art Unit	1635
Examiner Name	J. Schultz

Attorney Docket Number ISIS0054-100 (RTS-0201)

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input checked="" type="checkbox"/> Power of Attorney with Revocation and Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1) Table A
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2) Statement under 37 CFR 3.73(b) with executed Assignment
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	3) Return Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	RECEIVED SEP 26 2003 TECH CENTER 1600/2000
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Paul K. Legaard, Registration No. 38,534
Signature	
Date	September 18, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date: September 18, 2003

Typed or printed name	Paul K. Legaard, Registration No. 38,534
Signature	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

I hereby revoke all previous powers of attorney or authorizations of agent given in the
patents/applications identified in Table A attached hereto, and appoint ~~PLATINUM INNOVATION GROUP~~

BAR CODE 34138
PATENT TRADEMARK OFFICE

Practitioners at Customer Number: 34138

as my/our attorney(s) or agent(s) to prosecute the patents/applications identified in Table A,
and to transact all business in the United States Patent and Trademark Office connected
therewith.

Please change the Correspondence Address for the patent applications identified in
Table A to:

Practitioners at Customer Number: 34138


I am the:

Applicant/Inventor.

Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b)
is enclosed.)

Respectfully submitted,
ISIS PHARMACEUTICALS, INC.

Date: 7/22/2003

By: 

Name: B. Lynne Parshall
Title: Executive Vice President



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, **ISIS Pharmaceuticals, Inc.**, a corporation, states that it is:

the assignee of the entire right, title, and interest of the patents/applications identified in Table A attached hereto.


The extent (by, percentage) of its ownership interest is 100% in the patents/applications identified in Table A.

a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,
ISIS PHARMACEUTICALS, INC.

Date: 7/22/2003

By: 

Name: B. Lynne Parshall
Title: Executive Vice President

A S S I G N M E N T

WHEREAS, we Hong Zhang, residing at 3339 Cadencia St Carlsbad CA 92009 and Andrew T. Watt, residing at 1500 Shadowridge Dr.. Apt. 154 Vista CA 92083 hereinafter referred to as the assignors, are the joint inventors of certain inventions or improvements for which we have made application for Letters Patent to the United States, entitled **Antisense Modulation of caspase 7 Expression**; filed concurrently herewith; and

WHEREAS, **Isis Pharmaceuticals Inc.** hereinafter referred to as the assignee, of **2292 Faraday Ave, Carlsbad, California 92008** is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in consideration of the sum of One Dollar (\$1.00) to each of us in hand paid by said assignee, and other good and valuable consideration, the receipt of which is hereby acknowledged, we, the said assignors, have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said application and any and all continuations, divisions and renewals of and substitutes for said application, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in our names applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

AND we hereby covenant that we have full right to convey the entire interest herein assigned, and that we have not executed and will not execute any agreement in conflict herewith, and we further covenant and agree that we will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees, or legal representatives, and each of us agrees to communicate to said assignee or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

DOCKET NO.:RTS-0201

AND we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

We further authorize and direct our attorneys to insert below* the serial number and filing date of said application as soon as the same shall have been made known to them by the United States Patent Office.

IN WITNESS WHEREOF, we have hereunto set our hands and seals.

Dated: 9-6-00


Hong Zhang

STATE OF California)
COUNTY OF San Diego) ss.

This 6th day of September, before me personally came the above-named Hong Zhang, who executed the foregoing Assignment in my presence, and who acknowledged to me that he/she executed the same of his/her own free will for the purposes set forth therein.




Lane B.D. Schwartz
Notary Public for San Diego, Ca
My commission expires: 9-13-02


DOCKET NO.: RTS-0201

Dated: 09/07/00


Andrew T. Watt

STATE OF California)
COUNTY OF San Diego) ss.
)

This 7th day of September, 2000, before me personally
came the above-named Andrew T. Watt, who executed the foregoing
Assignment in my presence, and who acknowledged to me that he/she
executed the same of his/her own free will for the purposes set forth
therein.






Lane B.D. Schwartz
Notary Public for San Diego, CA
My commission expires: 9-13-02

Table A

Serial No. Patent No. Docket No.	Filing Date Issue Date	Inventor(s)	Examiner	Art Unit	Title
09/577,902 6,284,538 ISIS0004-102	May 24, 2000 September 4, 2001	B. Monia et al.	M. Schmidt	1635	ANTISENSE INHIBITION OF PTEN EXPRESSION
09/048,810 6,238,921 ISIS0052-101	March 26, 1998 May 29, 2001	L. Miraglia et al.	M. Shibuya	1635	ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN MDM2 EXPRESSION
09/280,805 6,184,212 ISIS0052-102	March 26, 1999 February 6, 2001	L. Miraglia et al.	J. Epps	1635	ANTISENSE MODULATION OF HUMAN MDM2 EXPRESSION
09/731,457 ISIS0053-100	December 6, 2000	I. Popoff et al.	J. Schultz	1635	ANTISENSE MODULATION OF DAMAGE SPECIFIC DNA BINDING PROTEIN 1, P127 EXPRESSION
09/659,860 ISIS0054-100	September 11, 2000	H. Zhang et al.	J. Schultz	1635	ANTISENSE MODULATION OF CASPASE 7 EXPRESSION
10/007,078 ISIS0055-100	November 8, 2001	D. Ward et al.	J. Schultz	1635	ANTISENSE MODULATION OF EIF2C1 EXPRESSION
09/953,611 ISIS0056-100	September 13, 2001	D. Ward et al.	To Be Determined	1635	ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION
09/715,983 ISIS0057-100	November 20, 2000	B. Monia et al.	J. Zara	1635	ANTISENSE MODULATION OF PI3K P85 EXPRESSION
09/344,521 6,100,090 ISIS0057-101	June 25, 1999 August 8, 2000	B. Monia et al.	J. Zara	1635	ANTISENSE INHIBITION OF PI3K P85 EXPRESSION
09/954,679 ISIS0058-100	September 12, 2001	D. Ward et al.	K. Lacourriere	1635	ANTISENSE MODULATION OF RIBONUCLEASE L EXPRESSION
09/484,617 6,303,374 ISIS0059-100	January 18, 2000 October 16, 2001	H. Zhang et al.	S. McGarry	1635	ANTISENSE MODULATION OF CASPASE 3 EXPRESSION

RECEIVED
SEP 26 2003
SEARCH CENTER 1600/2900



Serial No. Patent No. Docket No.	Filing Date Issue Date	Inventor(s)	Examiner	Art Unit	Title
09/679,298 6,566,131 ISIS0060-100	October 4, 2000 May 20, 2003	L. Cowser	M. Schmidt	1635	ANTISENSE MODULATION OF SMAD6 EXPRESSION
09/679,299 6,566,135 ISIS0061-100	October 4, 2000 May 20, 2003	A. Watt	J. Zara	1635	ANTISENSE MODULATION OF CASPASE 6 EXPRESSION
09/853,768 6,444,466 ISIS0062-100	May 10, 2001 September 3, 2002	D. Ward et al.	J. LeGuyader	1635	ANTISENSE MODULATION OF HELICASE-MOI EXPRESSION
10/001,863 ISIS0063-100	November 19, 2001	J. Karras et al.	To Be Determined	1645	ANTISENSE MODULATION OF TOLL-LIKE RECEPTOR 4 EXPRESSION
09/865,993 ISIS0064-100	May 25, 2001	B. Monia et al.	J. Zara	1635	ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 5 EXPRESSION
09/667,018 ISIS0065-100	September 20, 2000	H. Zhang et al.	J. Schultz	1635	ANTISENSE MODULATION OF CASPASE 2 EXPRESSION
10/271,887 ISIS0066-100	October 15, 2002	H. Zhang et al.	To Be Determined	1635	ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
09/659,845 6,492,170 ISIS0066-101	September 11, 2000 December 10, 2002	A. Watt	A. Wang	1639	ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
10/309,362 ISIS0067-100	December 3, 2002	D. Ward et al.	To Be Determined	1635	ANTISENSE MODULATION OF RECQL5 EXPRESSION
10/238,443 ISIS0067-101	September 9, 2002	D. Ward et al.	To Be Determined	1635	ANTISENSE MODULATION OF RECQL5 EXPRESSION
09/798,185 ISIS0067-102	March 1, 2001	D. Ward et al.	K. Lacourciere	1635	ANTISENSE MODULATION OF RECQL5 EXPRESSION
09/798,096 6,399,378 ISIS0068-100	March 1, 2001 June 4, 2002	D. Ward et al.	S. McGarry	1635	ANTISENSE MODULATION OF RECQL2 EXPRESSION

RECEIVED
SEP 26 2003
CENTER 1600/2900

Serial No. Patent No. Docket No.	Filing Date Issue Date	Inventor(s)	Examiner	Art Unit	Title
09/792,594 6,436,706 ISIS0069-100	February 23, 2001 August 20, 2002	D. Ward et al.	K. Lacourriere	1635	ANTISENSE MODULATION OF RECQL4 EXPRESSION
09/793,807 ISIS0070-100	February 23, 2001	D. Ward et al.	J. Zara	1635	ANTISENSE MODULATION OF RECQL EXPRESSION
09/358,381 6,020,199 ISIS0071-100	July 21, 1999 February 1, 2000	B. Monia et al.	M. Schmidt	1635	ANTISENSE MODULATION OF PTEN EXPRESSION
10/006,430 ISIS0072-100	December 10, 2001	M. Graham et al.	S. McGarry	1635	ANTISENSE MODULATION OF CD81 EXPRESSION
10/175,492 ISIS0073-100	June 17, 2002	K. Dobie et al.	To Be Determined	1645	ANTISENSE MODULATION OF PAZ/PIWI DOMAIN CONTAINING PROTEIN EXPRESSION
10/199,221 ISIS0074-100	July 18, 2002	B. Monia et al.	J. Epps	1635	ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 6 EXPRESSION
09/487,444 6,159,697 ISIS0075-100	January 19, 2000 December 12, 2000	B. Monia et al.	A. Wang	1635	ANTISENSE MODULATION OF SMAD7 EXPRESSION
10/181,603 ISIS0075-101	July 17, 2002	B. Monia et al.	To Be Determined	1651	ANTISENSE MODULATION OF SMAD7 EXPRESSION
09/732,199 6,379,960 ISIS0076-100	December 6, 2000 April 30, 2002	I. Popoff et al.	M. Schmidt	1635	ANTISENSE MODULATION OF DAMAGE-SPECIFIC DNA BINDING PROTEIN 2, p48 EXPRESSION
09/920,668 6,482,644 ISIS0077-100	August 1, 2001 November 19, 2002	L. Cowser	M. Schmidt	1635	ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 8 EXPRESSION
09/922,146 6,566,133 ISIS0078-100	August 1, 2001 May 20, 2003	L. Cowser	T. Gibbs	1635	ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION

RECEIVED

SEP 26 2003

TECH CENTER 3
1600/2900



Serial No. Patent No. Docket No.	Filing Date Issue Date	Inventor(s)	Examiner	Art Unit	Title
09/487,445 6,258,600 ISIS0079-100	January 19, 2000 July 10, 2001	H. Zhang et al.	M. Shibuya	1635	ANTISENSE MODULATION OF CASPASE 8 EXPRESSION
10/181,177 ISIS0079-101	July 12, 2002	H. Zhang et al.	To Be Determined	1632	ANTISENSE MODULATION OF CASPASE 8 EXPRESSION



4

RECEIVED
SEP 26 2003
TECH CENTER 1600/2900